新型吲哚胺2,3-二加氧酶抑制剂及其治疗人类疾病的研究  

Research of the new indoleamine 2,3-dioxygenase inhibitors and its treatment of human diseases

作　　者：杨云云[1] 李锡帅[1] 杨青[1] 

机构地区：[1]复旦大学,上海200433

出　　处：《上海医药》2012年第9期16-19,共4页Shanghai Medical & Pharmaceutical Journal

基　　金：国家自然基金面上项目(30873153)

摘　　要：吲哚胺2,3-二加氧酶(indoleamine2,3-dioxygenase,IDO)是催化色氨酸沿犬尿氨酸代谢途径分解的限速酶,已被证实与肿瘤、阿尔茨海默病、抑郁症和白内障等多种人类疾病的发病机制密切相关。IDO抑制剂是具有新药靶、新机制的广谱药物,应用前景非常广阔。Indoleamine 2,3-dioxygenase（IDO） is a monomeric 45 kDa heme-containing dioxygenase that catalyzes the initial and rate limiting step of L-tryptophan（L-Trp） catabolism along the kynurenine pathway（KP）.IDO has been confirmed to have the close relationship of the pathogenesis mechanism with cancer,Alzheimer＇s disease,depression,age-related cataract as well as other diseases characterized by pathological tryptophan metabolism.It is a broad-spectrum agent with the new molecular target and mechanism,which has the promising application prospects.

关 键 词：吲哚胺2 3-二加氧酶 吲哚胺2 3-二加氧酶抑制剂 药物发现靶标 肿瘤 阿尔茨海默病 

分 类 号：R94[医药卫生—药剂学]